Loading organizations...
§ Private Profile · The Glenn Berge Building, Babraham, Cambridge, CB22 3FH, United Kingdom
Oncology diagnostics company developing liquid biopsy tests using circulating tumor DNA for cancer diagnosis, personalized therapy, and.
Key people at Inivata Limited.
Inivata Limited developed liquid biopsy tests using circulating tumor DNA (ctDNA) from a simple blood draw to diagnose cancer, guide personalized therapy, and monitor treatment response, based in Cambridge, UK. Leveraging its InVision platform and enhanced TAm-Seq technology, the company provided genomic insights for cancer patients and clinical trials, notably with products like InVisionFirst-Lung. It secured initial funding of £4 million in 2014 from investors including Cambridge Innovation Capital. NeoGenomics subsequently made a $25 million minority investment in May 2020 before fully acquiring Inivata for $390 million in May 2021, integrating its technology into a broader oncology diagnostics portfolio. The firm partnered with pharmaceutical companies and clinicians under CEO Clive Morris. Inivata was founded in 2014 as a Cancer Research UK spinout by Nitzan Rosenfeld, Tim Forshew, James Brenton, and Davina Gale.
Key people at Inivata Limited.
Inivata Limited is a clinical cancer genomics company specializing in liquid biopsy technologies that analyze circulating tumor DNA (ctDNA) from blood samples to enable earlier cancer detection, personalized treatment, and disease monitoring.[1][2][3] It develops products like the InVision® platform for genomic insights in advanced cancers (e.g., InVisionFirst®-Lung for NSCLC) and the RaDaR® assay for minimal residual disease (MRD) detection and recurrence monitoring, serving oncologists, cancer patients, pharmaceutical companies, and clinical trial designers.[1][3][4] Acquired by NeoGenomics in June 2021, Inivata now operates as a key liquid biopsy division within the larger oncology diagnostics provider, enhancing global R&D, CLIA/CAP-accredited testing, and commercialization across North America, Europe, and beyond, with strong growth through integration into NeoGenomics' network.[1][4]
The company addresses critical gaps in cancer care by offering non-invasive, highly sensitive alternatives to tissue biopsies, improving therapy selection, treatment monitoring, and resistance detection.[3][4] Post-acquisition, its momentum has accelerated via NeoGenomics' resources, including expanded pharma services and FDA Breakthrough Device Designation for RaDaR®, positioning it for broader clinical and commercial launches.[1][4]
Inivata was incorporated on July 23, 2014, in Cambridge, UK, emerging from pioneering research at the Cancer Research UK Cambridge Institute and University of Cambridge on ctDNA analysis.[1][2][4][5] Its scientific founders—Nitzan Rosenfeld, Tim Forshew (UCL Cancer Institute), James Brenton, and Davina Gale (all affiliated with Cancer Research UK Cambridge Institute)—brought deep expertise in cancer genomics and circulating DNA, applying enhanced TAm-Seq technology to real-world clinical needs.[2] The idea stemmed from academic breakthroughs in non-invasive cancer testing, quickly translating into commercial products like InVision® and RaDaR®.[1][4]
Early traction included international commercialization of InVisionFirst®-Lung, a CLIA-certified lab in Research Triangle Park, NC, and R&D in Cambridge's Babraham Research Campus.[1][4][5] Backed by investors like Cambridge Innovation Capital, Inivata raised $200 million in strategic financing before its 2021 acquisition by NeoGenomics, marking a pivotal shift to scaled operations under CEO Clive Morris (who became President of the Inivata division).[1][4][6]
Inivata rides the liquid biopsy wave in precision oncology, where ctDNA analysis transforms cancer care amid rising demand for non-invasive diagnostics amid aging populations and targeted therapies.[1][2][3] Timing aligns with post-2021 genomics boom, FDA nods for MRD tools, and pharma's shift to companion diagnostics for immunotherapies and ADCs.[4] Market forces like expanding clinical trials, global oncology services growth, and NeoGenomics' platform amplify its reach, influencing ecosystems by standardizing ctDNA for trials, reducing biopsy reliance, and enabling personalized medicine.[1][4]
As part of NeoGenomics, it bolsters the oncology diagnostics sector's consolidation, bridging academia (Cambridge roots) with commercial scale, and supports biotech/pharma in faster drug development.[1][6]
NeoGenomics' ownership positions Inivata for RaDaR®'s full clinical rollout and expanded ctDNA assays amid MRD market growth, with next steps including broader FDA approvals, international pharma deals, and AI-enhanced bioinformatics.[1][4] Trends like multi-omics integration, real-world evidence from trials, and liquid biopsy reimbursement will shape its path, potentially evolving its influence toward dominant MRD/recurrence monitoring in solid tumors. This builds on its origin as a Cambridge innovator, now powering global cancer care transformation through NeoGenomics' ecosystem.[1][4]
